A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors

被引：0
|
作者：
Biber, Josh [1 ]
Wan, Yin [1 ]
Churchill, Eric N. [2 ]
Danes, Christopher G. [2 ]
Socinski, Mark A. [3 ]
Spira, Alexander I. [4 ]
机构：
[1] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[2] Takeda Pharmaceut S Inc, Lexington, MA USA
[3] Advent Hlth Canc Inst, Orlando, FL USA
[4] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.80
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [1] Outcomes of ALK plus non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the clinical trial setting and in a referral Institution.
    Rojo, Ana Matres
    Felip, Enriqueta
    Dienstmann, Rodrigo
    Garces, Victor Navarro
    Viaplana, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [3] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Kim, D. W.
    Blackhall, F.
    Soria, J. C.
    Solomon, B.
    Camidge, D. R.
    Riely, G. J.
    Bottomley, A.
    Tassell, V.
    Polli, A.
    Shaw, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S617 - S617
  • [5] Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+non-small cell lung cancer (NSCLC)
    Peters, S.
    Shaw, A. T.
    Besse, B.
    Felip, E.
    Solomon, B. J.
    Soo, R. A.
    Bearz, A.
    Gadgee, S. M.
    Lin, C-C.
    Kao, S.
    Seto, T.
    Masters, E. T.
    Abbattista, A.
    Clancy, J. S.
    Thurm, H.
    Reisman, A.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES (PROS) WITH CRIZOTINIB VERSUS CHEMOTHERAPY IN ASIAN PATIENTS IN A PHASE III STUDY OF PREVIOUSLY TREATED ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Nishio, Makoto
    Hirsh, Vera
    Kim, Dong-Wan
    Wilner, Keith D.
    Polli, Anna
    Reisman, Arlene
    Iyer, Shrividya
    Blackhall, Fiona
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S198 - S199
  • [7] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    Waterhouse, David M.
    Espirito, Janet L.
    Chioda, Marc D.
    Baidoo, Bismark
    Mardekian, Jack
    Robert, Nicholas J.
    Masters, Elizabeth T.
    DRUGS-REAL WORLD OUTCOMES, 2020, 7 (04) : 261 - 269
  • [8] Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK plus non-small cell lung cancer (NSCLC).
    Langer, Corey J.
    Huang, Hui
    Huang, Joice
    Kerstein, David
    Reichmann, William
    Speck, Rebecca M.
    Lenderking, William R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    David M. Waterhouse
    Janet L. Espirito
    Marc D. Chioda
    Bismark Baidoo
    Jack Mardekian
    Nicholas J. Robert
    Elizabeth T. Masters
    Drugs - Real World Outcomes, 2020, 7 : 261 - 269
  • [10] Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea
    Lim, Sung Hee
    Yoh, Kyung Ah
    Lee, Jong Seok
    Ahn, Myung-ju
    Kim, Yu Jung
    Kim, Se Hyun
    Zhang, Jie
    Patel, Dony
    Swallow, Elyse
    Kageleiry, Andrew
    Galebach, Philip
    Lee, Dongyeol
    Stein, Karen
    Degun, Ravi
    Park, Keunchil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E239 - E245
12345